In this stdy, patients aged above 6 months with symptomatic malaria presenting to health
centers will be enrolled for treatment with artemether-lumefantrine for P. falciparum
infection, and either artemether-lumefantrine or chloroquine for P. vivax infection.
Clinical, parasitologic, and hematologic parameters will be monitored for P. falciparum and
P. vivax infection over a 42-day follow-up period, which will be used to evaluate drug
efficacy. Results from this research study will be used to assist Ethiopia in assessing their
current national malaria drug policies.
Phase:
N/A
Details
Lead Sponsor:
Centers for Disease Control and Prevention
Collaborators:
Columbia University United States Agency for International Development (USAID)